⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912026 | 0.92 | — | — | |
| SCHEMBL25912032 | 0.92 | — | — | |
| SCHEMBL25912014 | 0.90 | — | — | |
| SCHEMBL25911999 | 0.90 | — | — | |
| SCHEMBL25911643 | 0.89 | RNASEL (0.33) | — | |
| SCHEMBL24916832 | 0.88 | TMPRSS2 (0.37) | — | |
| SCHEMBL25912701 | 0.88 | RNASEL (0.31) | — | |
| SCHEMBL24789713 | 0.88 | DOT1L (0.30) | — | |
| SCHEMBL24917123 | 0.88 | CA12 (0.36) | — | |
| SCHEMBL24916833 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |